AN2 Therapeutics Other Current Liabilities

The latest other current liabilities for ANTX is $3.6M as of June 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside AN2 Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ANTX's other current liabilities moved from $0 to $3.6M. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AN2 Therapeutics's operating scale or balance-sheet position.

A other current liabilities figure of $3.6M for ANTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ANTX's other current liabilities ($3.6M), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.